ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
Listen now
Description
The gene therapy is administered using a less-invasive intravitreal injection.
More Episodes
Dr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in...
Published 06/07/24
Published 06/07/24
Researchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
Published 06/05/24